All In Biotech

Drug Trial Radar · NCT01030861

Teplizumab for Prevention of Type 1 Diabetes In Relatives "At-Risk"

AntiCD3 Mab (Teplizumab) For Prevention of Diabetes In Relatives At-Risk for Type 1 Diabetes Mellitus

Last checked: Nov 20, 2026Latest source record: Aug 5, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

76

Actual

Start

Aug 2010

Primary completion

Nov 2018

Study completion Jun 2019

Sponsor

Sponsor type
NIH
Collaborators
National Institute of Allergy and Infectious Diseases (NIAID); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); National Center for Research Resources (NCRR); Juvenile Diabetes Research Foundation; American Diabetes Association
First posted
Dec 14, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 8 years, up to 45 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study will determine whether the anti-CD3 monoclonal antibody, teplizumab, can help to prevent or delay the onset of type 1 diabetes (T1D) in relatives determined to be at very high risk for developing the disease. Teplizumab has been studied in new onset type 1 diabetes for testing of efficacy and safety in previous studies; other studies are currently in progress. The results of previous studies indicate that teplizumab reduces the loss of insulin production during the first year after diagnosis in individuals with type 1 diabetes. The purpose of this study is to determine if teplizumab can interdict the immune process that causes the destruction of insulin secreting beta cells in the pancreas during the "pre-diabetic" state and thereby prevent or delay the onset of type 1 diabetes.

Conditions

  • Autoantibody Positive
  • Non-diabetic Relatives at Risk for Type 1 Diabetes
  • High Risk
  • Impaired Glucose Tolerance

Interventions

  • TeplizumabDrug

    intravenous infusions

  • Placebo infusionDrug

    Placebo for Teplizumab

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Rate of New Diabetes Per YearTime frame: During follow-up, median 745 days, range 74 to 2683

Locations

19 sites in 3 countries. Site status is shown where the registry gives one.

  • University of California in San Francisco

    San Francisco, California

  • University of California-San Francisco

    San Francisco, California

  • Stanford University

    Stanford, California

  • Barbara Davis Center for Childhood Diabetes/ University of Colorado

    Denver, Colorado

  • Yale University School of Medicine

    New Haven, Connecticut

  • University of Florida

    Gainesville, Florida

  • University of Miami

    Miami, Florida

  • University of South Florida

    Tampa, Florida

  • Indiana University

    Indianapolis, Indiana

  • University of Minnesota

    Minneapolis, Minnesota

  • The Children's Mercy Hospital

    Kansas City, Missouri

  • Columbia University

    New York, New York

  • University of Pittsburgh

    Pittsburgh, Pennsylvania

  • Vanderbilt University

    Nashville, Tennessee

  • University of Texas

    Dallas, Texas

  • Baylor College of Medicine

    Houston, Texas

  • Benaroya Research Institute

    Seattle, Washington

  • The Hospital for Sick Children

    Toronto, Ontario, Canada

  • Forschergruppe Diabetes

    Munich, Germany

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.